FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress

Roberto Ronca1, Gaia C Ghedini1, Federica Maccarinelli1

  • 1Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Cancer Research
|February 26, 2020
PubMed

Insights

Fibroblast growth factor (FGF) signaling is crucial for multiple myeloma cell survival. Blocking FGF/FGFR pathways induces oxidative stress and apoptosis, offering a potential therapeutic strategy for resistant and high-risk multiple myeloma.

Area of Science:

  • Hematologic Malignancies
  • Cancer Biology
  • Molecular Oncology

Background:

  • Multiple myeloma (MM) is the second most common hematologic malignancy, often characterized by relapse due to chemotherapeutic resistance.
  • Fibroblast growth factors (FGF) and their receptors (FGFR) are implicated as proangiogenic and mitogenic factors in MM progression.

Purpose of the Study:

  • To investigate the role of the autocrine FGF/FGFR axis in MM cell survival and progression.
  • To explore the potential of targeting the FGF/FGFR axis as a therapeutic strategy for MM, particularly in resistant cases.

Main Methods:

  • Utilized FGF trapping and tyrosine kinase inhibitors to block FGF/FGFR signaling in MM cells.
  • Assessed the impact of FGF/FGFR blockade on oxidative stress, DNA damage, apoptosis, and c-Myc oncoprotein levels.
  • Investigated the role of proteasomal degradation and glutathione depletion in the observed effects.
  • Validated findings in bortezomib-resistant MM cells and primary patient samples, including high-risk MM.

Main Results:

  • The autocrine FGF/FGFR axis is essential for MM cell survival, protecting against oxidative stress-induced apoptosis.
  • FGF/FGFR blockade induces mitochondrial oxidative stress, DNA damage, and apoptosis, which can be rescued by antioxidants.
  • Proteasomal degradation of c-Myc leads to glutathione depletion and sensitizes MM cells to FGF blockade.
  • Targeting FGF/FGFR is effective in bortezomib-resistant MM and primary patient cells, including those with high-risk translocations.

Conclusions:

  • The FGF/FGFR system plays a critical, nonredundant role in MM cell survival and disease progression.
  • FGF/FGFR blockade represents a promising therapeutic strategy for patients with poor prognosis and advanced-stage multiple myeloma.
  • Understanding the interplay between FGF/FGFR signaling, oxidative stress, and c-Myc is key to developing novel MM therapies.